Forecast
The analysts' average price target is €20.96 (+308.58%). The median is €22.78 (+344.05%).
| Buy |
Â
17 |
| Hold |
Â
2 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Ocular Therapeutix on track to submit NDA for AXPAXLI after positive pre‑NDA meeting
Ocular Therapeutix completed a positive FDA pre‑NDA meeting and plans to file the NDA for AXPAXLI in Q4 2026, supported by Week 52 SOL‑1 data and interim SOL‑R results. SOL‑1 showed superiority to aflibercept with durable vision benefits and up to 72% fewer injections over 60 weeks, and the company expects a potential 2027 launch if approved. The firm faces widening cash burn and net losses, reliance on a single marketed product for revenue, and extended SOL‑R endpoints now pushing additional topline data to Q1 2028. Market positioning is polarized with rising institutional interest but elevated short interest around 15% of the float. » More on finance.yahoo.com
Ocular Therapeutix stock climbs after EyePoint study failure
Ocular Therapeutix’s stock rose after it became known that EyePoint Pharmaceuticals’ phase‑3 LUGANO study of DURAVYU did not meet the primary endpoint in wet AMD. The trial failure temporarily reduces competitive pressure on Ocular’s candidate AXPAXLI, which, after a positive FDA type‑C meeting, is aiming to file an accelerated approval application (505(b)(2)) at the end of 2026. Ocular reports longer durability and favorable safety data versus aflibercept in the phase‑3 SOL‑1 study and is targeting a 2027 market launch. The stock reached an intraday high of $11.16 and later traded around $10.67. » More on de.investing.com
Ocular Therapeutix: FDA agrees to approval pathway for AXPAXLI based on a single study
According to a presentation at the H.C. Wainwright conference, Ocular Therapeutix has reached an agreement with the FDA to submit the full approval package for AXPAXLI based on a single study; a submission is planned for Q4 2024 and the pre-NDA meeting in Q3 2024 is expected to be purely operational. The SOL-1 data, the company says, meet masking and statistical power requirements and show a p-value <0.0006; the safety profile through week 52 is clean, with no endophthalmitis or retinal vasculitis. Ocular Therapeutix had $667 million in liquidity (end of Q1) and expects to be funded through 2028 and beyond the product launch. » More on de.investing.com
High options activity at Ocular Therapeutix, calls dominate trading
Options trading volume on Ocular Therapeutix rose to 9,894 contracts, of which 9,882 were calls and 12 were puts. The most heavily traded was the call expiring July 17, 2026 with a strike price of $9 (9,807 contracts); open interest stood at 10,160 contracts as of July 2. The stock fell 0.88% to $9.56, three-month volatility fell to 99.76%, and the three-month skew (90/110) rose to 10.00 percentage points. » More on de.investing.com
Ocular Therapeuticx advances Axpaxli regulatory plan after positive FDA Type C feedback
Ocular Therapeuticx reported favorable feedback from a Type C meeting with the FDA, prompting H.C. Wainwright to raise its price target and increase confidence in Axpaxli's approval and commercial potential. The company plans to submit a New Drug Application in Q4 2026 using SOL-1 efficacy/safety data and interim SOL-R safety results, and has revised SOL-R to collect additional endpoints through Week 96. Ocular Therapeuticx also narrowed its non‑proliferative diabetic retinopathy program to focus resources on the Phase 3 HELIOS-3 trial. » More on finance.yahoo.com
Financials
In the last quarter, Ocular Therapeutix had revenue of €11.37M and net profit of -€83.68M
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 11.37M | 8.29% |
| Gross profit | 10.08M | 7.36% |
| Net profit | -83.68M | 41.46% |
| EBITDA | -79.05M | 41.96% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.12B |
Number of shares | 220.02M |
52-week high/low | €14.98 - €5.05 |
| Dividends | No |
Beta | 0.99 |
P/E ratio | -3.82 |
PEG ratio | 2.48 |
P/B ratio | 2.85 |
P/S ratio | 24.32 |
Company profile
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
| Name | Ocular Therapeutix |
| CEO | Pravin U. Dugel |
| Headquarters | Bedford,
ma USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 07/25/2014 |
| Employees | 325 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | OCUL |
Frankfurt | 0OT.F |
DĂĽsseldorf | 0OT.DU |
SIX | 0OT.SW |